Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

@article{Lannfelt2008SafetyEA,
  title={Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.},
  author={Lars Lannfelt and K Blennow and Henrik Zetterberg and Stellan B{\aa}tsman and David Ames and John Kevin Harrison and Colin L. Masters and Steve Targum and Ashley I. Bush and Ross Murdoch and Janet P Wilson and Craig William Ritchie},
  journal={The Lancet. Neurology},
  year={2008},
  volume={7 9},
  pages={779-86}
}
BACKGROUND PBT2 is a metal-protein attenuating compound (MPAC) that affects the Cu2(+)-mediated and Zn2(+)-mediated toxic oligomerisation of Abeta seen in Alzheimer's disease (AD). Strong preclinical efficacy data and the completion of early, clinical safety studies have preceded this phase IIa study, the aim of which was to assess the effects of PBT2 on safety, efficacy, and biomarkers of AD. METHODS Between December 6, 2006, and September 21, 2007, community-dwelling patients over age 55… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 210 extracted citations

Similar Papers

Loading similar papers…